Several possible studies
Story checked
INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar (opens in a new tab)
news-medical.net · 2026-10-22
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar
news-medical.net · 2026-10-22
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedINmune Bio entered into a Master Services Agreement with Uniphar to establish a scalable framework for international access, distribution and commercialization of Ebstrocel™.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 4Not checkedThe company initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa, subject to applicable law and country-specific statements of work.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 4Not checkedINmune Bio says named-patient access may be an important component of its international commercialization strategy and could eventually expand to broader commercial distribution as regulatory approvals, pricing and reimbursement are secured.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 4Not checkedEbstrocel™ (pobistrocel) is described as an investigational pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed through INmune Bio’s CORDStrom™ platform for recessive dystrophic epidermolysis bullosa.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial.
Orphanet Journal of Rare Diseases · 2026 · PubMed, Europe PMC
Study to evaluate the use of allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa
Http://isrctn.org/> · 2012 · Crossref
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase.
EClinicalMedicine · 2025 · PubMed
Faculty Opinions recommendation of Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2018 · Crossref
Identification of a long-term surviving human mesenchymal stromal cell subpopulation and implications for recessive dystrophic epidermolysis bullosa treatment.
2026 · Europe PMC